Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Insulin: Evidence Summary
Evidence summary for Insulin across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Insulin overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Type 1 diabetes | Tier A | 200 | Life-sustaining; DCCT showed 76% retinopathy reduction with intensive control |
| Type 2 diabetes | Tier A | 300 | UKPDS showed 12% reduction in diabetes-related death |
| Diabetic ketoacidosis | Tier A | 50 | Standard of care — IV insulin infusion protocol |
| Hyperkalemia | Tier A | 20 | IV insulin + glucose is standard of care for acute hyperkalemia |
References (6)
- The effect of intensive treatment of diabetes on the development of long-term complications in IDDM — The Diabetes Control and Complications Trial Research Group . New England Journal of Medicine (1993) PMID: 8366922
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment — UK Prospective Diabetes Study (UKPDS) Group . Lancet (1998) PMID: 9742976
- Effects of intensive glucose lowering in type 2 diabetes — The ACCORD Study Group . New England Journal of Medicine (2008) PMID: 18539917
- Efficacy and safety of degludec vs glargine in type 2 diabetes — Marso SP, et al. . New England Journal of Medicine (2017) PMID: 28605603
- Intensive insulin and hypoglycemia mortality: systematic review — Multiple authors . Diabetes Care (2019)
- Insulin analogs versus human insulin: systematic review — Multiple authors . Cochrane Database of Systematic Reviews (2012) PMID: 17410596